Drug Therapy Guidelines
|
|
- Gillian Jefferson
- 5 years ago
- Views:
Transcription
1 Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide), Firazyr (icatibant), Rucnest (C1 esterase inhibitr [recmbinant]), Takhzyr TM (lanadelumab-fly) Medical Benefit x Effective: 1/3/19 Pharmacy- Frmulary 1 x Next Review: 6/19 Pharmacy- Frmulary 2 x Date f Origin: 3/09 Pharmacy- Frmulary 3/Exclusive x Review Dates: 10/15/06, 11/5/07, 12/15/08,12/09, 12/10, 12/11, Pharmacy- Frmulary 4/AON x 12/12, 12/13, 12/14, 6/15, 6/16, 9/17, 6/18, 9/18 I. Medicatin Descriptin Hereditary Angiedema (HAE) is an autsmal dminant disease caused by mutatin f the C1 inhibitr gene (SERPING1), resulting in lw levels f C1 inhibitr prtein, r lss f functinality f this prtein. Althugh multiple mutatins have been identified, the exact cause f HAE is still unclear. C1 inhibitr prtein plays a rle in fur enzymatic cascades in the bdy, all f which are interrelated t eventually cause the prductin f the peptide bradykinin. Deficiency in C1 inhibitr prtein results in lack f inhibitin f these cascades and increased levels f bradykinin. This uninhibited prductin f bradykinin causes angiedema in patients with HAE. Labratry measurement f C1-INH, C1-INH activity and serum C4 levels are perfrmed fr diagnsis. II. Psitin Statement Cverage is prvided thrugh a prir authrizatin prcess with supprting clinical dcumentatin fr every request. Medical benefit drugs: Cinryze (when administered by a healthcare prfessinal) Haegarda (when administered by a healthcare prfessinal) Berinert (when administered by a healthcare prfessinal) Rucnest (when administered by a healthcare prfessinal) Kalbitr Takhzyr (when administered by a healthcare prfessinal) Pharmacy benefit drugs: Berinert (when self-administered) Cinryze (when self-administered) Firazyr Haegarda (when self-administered) Rucnest (when self-administered) Takhzyr (when self-administered) Page 1 f 6
2 III. Plicy In all cases, the diagnsis f Hereditary Angiedema (HAE) must have (at sme time) been cnfirmed by an allergist, immunlgist, r hematlgist. Cverage f the prphylactic use f Cinryze, Haegarda, r Takhzyr is prvided fr the fllwing: Fr lng-term prphylaxis against angiedema attacks when: The disease is severely symptmatic AND The member is at least: 6 years f age fr Cinryze 10 years f age fr Haegarda 12 years f age fr Takhzyr AND When requesting cverage f a brand medicatin fr which an A/B rated generic is available, cverage will be prvided when there is sufficient evidence that the use f the A/B rated generic equivalent has resulted in inadequate results AND Cverage will be prvided when the member has experienced intlerance r therapeutic failure with ONE plan-preferred medicatin such as attenuated andrgen (i.e. Danazl) r antifibrinlytic (i.e. tranexamic acid) first OR when at least ONE f the fllwing criteria have been met: The plan-preferred medicatins are cntraindicated r will likely cause an adverse reactin by r physical r mental harm t the member. The plan-preferred medicatins are expected t be ineffective based n the knwn clinical histry and cnditins f the member and the member s prescriptin drug regimen. The member has tried the plan-preferred medicatins r anther prescriptin drug in the same pharmaclgic class r with the same mechanism f actin and such prescriptin drug was discntinued due t lack f efficacy r effectiveness, diminished effect, r an adverse event. The member is stable n the medicatin selected by their healthcare prfessinal fr the medical cnditin under cnsideratin (where stable is defined as receiving the medicatin fr an adequate perid f time, have achieved ptimal respnse, and cntinued favrable utcmes are expected UNLESS the medicatin was initially selected slely due t the availability f a drug sample r a cupn card and the member des nt therwise meet the definitin f stable ). The plan-preferred medicatin is nt in the best interest f the member because it will likely cause a significant barrier t the member s adherence r t cmpliance with the member s plan f care, will likely wrsen a cmrbid cnditin f the member, r will likely decrease the member s ability t achieve r maintain reasnable functinal ability in perfrming daily activities. Fr shrt-term prphylaxis against angiedema attacks: Befre surgeries, where endtracheal intubatin is required, where upper airway r pharynx is manipulated, r befre brnchscpy r endscpy AND When the member is at least 6 years f age Page 2 f 6
3 Cverage f the fllwing is prvided fr acute treatment f HAE attacks: Cinryze when the member is at least 6 years f age Haegarda when the member is at least 10 years f age Kalbitr when the member is at least 12 years f age Rucnest when the member is at least 13 years f age Firazyr when the member is at least 18 years f age Berinert when the member is at least 6 years f age IV. Quantity Limitatins Haegarda Medical benefit: sufficient quantity t allw a dse f 60 internatinal units (6 billable units)/kg bdy weight twice weekly Pharmacy benefit: sufficient quantity t allw a dse f 60 internatinal units/kg bdy weight twice weekly Cinryze Medical benefit: 1000 billable units/30 days Pharmacy benefit: 20 vials/30 days Berinert Medical benefit: 800 billable units/30 days Pharmacy benefit: 16 vials/30 days Kalbitr Medical benefit: 240 billable units/30 days Firazyr Pharmacy benefit: 4 syringes/30 days Rucnest Medical benefit: 1680 billable units/30 days Pharmacy benefit: 8 vials/30 days Takhzyr Medical benefit: up t 2 vials/28 days Pharmacy benefit: up t 2 vials/28 days Additinal quantities f each medicatin may be available thrugh cverage review f supprting dcumentatin (i.e., bdy weight, frequency f attacks, etc.). V. Cverage Duratin Cverage is prvided fr 6 mnths and may be renewed. Cverage f shrt-term prphylaxis is limited t 1 mnth. VI. Cverage Renewal Criteria Cverage can be renewed based upn the fllwing criteria: Prphylaxis f hereditary angiedema attacks: Page 3 f 6
4 Dcumentatin must be prvided f a decrease in frequency f HAE attacks versus baseline and/r significant imprvement in the severity r duratin f attacks AND Absence f significant adverse reactin r txicity t medicatin is shwn Acute treatment f hereditary angiedema attacks: Subsequent requests will be authrized based n dcumentatin that member has respnded t prir treatments AND Absence f significant adverse reactin r txicity t medicatin is shwn VII. Billing/Cding Infrmatin Haegarda Haegarda is available as single-use vials cntaining 2000 r 3000 IU f C1-INH Medical when administered by a healthcare prfessinal Pharmacy when self-administered C9015: 1 billable unit = 10 units f drug Cinryze: Medical when administered by a healthcare prfessinal Pharmacy when self-administered Medical J0598 (1 billable unit = 10 units f drug) Pharmacy- 500 units f drug per each single-use vial Berinert: Medical when administered by a healthcare prfessinal Pharmacy when self-administered Medical- J0597 (1 billable unit = 10 units f drug) Pharmacy- 500 units f drug per each single-use vial Kalbitr: Medical benefit nly J1290 (1 billable unit = 1mg f drug; 10mg/ml single use vials cntaining 10mg each, 3 vials per cartn) Firazyr: Pharmacy benefit nly 3ml prefilled syringe (10mg/ml) Rucnest: Medical when administered by a healthcare prfessinal Pharmacy when self-administered Medical J0596 (1 billable unit = 10 units f drug) Pharmacy 2100 IU f drug per each single use vial Takhzyr: Medical when administered by a healthcare prfessinal Pharmacy benefit when self-administered Medical J3590 (1 billable unit = 1 vial) C9399 (1 billable unit = 1 vial) Page 4 f 6
5 300 mg/2 ml (150 mg/ml) slutin in single-dse glass vial Related diagnsis: Other deficiencies f circulating enzymes: D84.1 VIII. Summary f Plicy Changes 9/1/11: Remved requirement f trial f C-1 esterase inhibitr prir t Kalbitr Renewal criteria defined 6/15/12: Firazyr added t plicy 6/2012: Cinryze and Berinert made available under the pharmacy benefit 3/15/13: n changes 3/15/14: Allwed Berinert fr prphylaxis if requested Simplified acute attack cverage criteria Expanded shrt-term prphylaxis cverage situatins 10/22/14: Rucnest added t plicy 3/15/15: change in age requirement fr cverage f Kalbitr 7/1/15: frmulary distinctins made 9/15/15: change in age requirement fr Cinryze and Berinert (frm 13 years t 12 years) 1/1/16: drug cde updated fr Rucnest 7/19/16: n plicy changes 5/1/17: step therapy criteria added 6/21/17: updated age limitatins and Berinert use 1/1/18: Haegarda added; updated age requirements 6/15/18: n plicy changes 11/1/18: Takhzyr added; updated age requirements 1/3/19: updated billing/cding infrmatin IX. References 1. Berinert [C-1 esterase inhibitr (human)] prescribing infrmatin, CSL Behring LLC, Kankakee IL 60901, Revised 9/ Cinryze [C-1 esterase inhibitr (human)] prescribing infrmatin, VirPharma Incrprated, Extn PA 19341, Revised 12/ Kalbitr (ecallantide), prescribing infrmatin, Dyax Crp., Cambridge MA 02139, Revised 3/ Firazyr (icatibant), prescribing infrmatin, Shire Orphan Therapies Inc., Lexingtn MA 02421, Revised 12/ Rucnest [C1 esterase inhibitr [recmbinant]), prescribing infrmatin, Santarus Inc. Raleigh, NC Revised 12/ UpTDate, retrieved May 2015 Page 5 f 6
6 7. Clinical Pharmaclgy, Accessed 5/ Facts and Cmparisns On-line, retrieved May Zuraw B, Lumry W, Hurewitz D, et al. Results f pen-label administratin f nanfiltered C1-inhibitr fr the treatment f acute HAE attacks. Abstract presented at the American Cllege f Allergy, Asthma, and Immunlgy Annual Scientific Meeting. Seattle, WA; 2008 Nv Abstract Zuraw B, Schaefer O, Grant JA, et al. Results f a randmized duble-blind placeb cntrlled study f nanfiltered C1-inhibitr fr the treatment f HAE attacks. Abstract presented at the American Cllege f Allergy, Asthma, and Immunlgy Annual Scientific Meeting. Dallas, TX; 2007 Nv Abstract Bwen T, Cicardi M, Farkas H, et al Internatinal cnsensus algrithm fr the diagnsis, therapy and management f hereditary angiedema. Allergy Asthma Clin Immunl. 2010;6(1): Farkas H, Gyeney L, Gidófalvy E, Füst G, Varga L. The efficacy f shrt-term danazl prphylaxis in hereditary angiedema patients underging maxillfacial and dental prcedures. J Oral Maxillfac Surg. 1999;57(4): Craig T, Pursun EA, Brk K, et. al. WAO Guideline fr the Management f Hereditary Angiedema. WAO Jurnal 2012; 5: Dunkle, M. (2011). Natinal Organizatin fr Rare Disrders (NORD). Encyclpedia f Clinical Neurpsychlgy, Haegarda (C-1 esterase inhibitr[human]) prescribing infrmatin. CSL Behring LLC, Kankakee IL. Revised 07/ Adlescent Health. Wrld Health Organizatin. WHO Web. Accessed 12/21/ Centers fr Medicare and Medicaid Services. Medicare Benefit Plicy Manual: Chapter 15. (CMS Publicatin N ). Retrieved frm Takhzyr TM (lanadelumab-fly) prescribing infrmatin. Dyax Crp, Lexingtn, MA. Revised *These guidelines are nt applicable t benefits cvered under Medicare Advantage. Medicare Advantage benefit cverage requests are reviewed in accrdance with the guidance set frth in Chapter 15 Sectin 50 f the Centers fr Medicare & Medicaid Services Medicare Benefit Plicy Manual. The Plan fully expects that nly apprpriate and medically necessary services will be rendered. The Plan reserves the right t cnduct pre-payment and pst-payment reviews t assess the medical apprpriateness f the abve-referenced therapies. The preceding plicy applies nly t members fr whm the abve named pharmacy benefit medicatins are included n their cvered frmulary. Members with clsed frmulary benefits are subject t trying all apprpriate frmulary alternatives befre a cverage exceptin fr a nn-frmulary medicatin will be cnsidered. The preceding plicy is a guideline t allw fr cverage f the pertinent medicatin/prduct, and is nt meant t serve as a clinical practice guideline. Page 6 f 6
Drug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 1/1/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 5/28/06 Pulmnary Arterial Hypertensin : Revati (sildenafil), Ventavis (ilprst),
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:
Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 6/18 Pharmacy- Frmulary 2 x Date f Origin: 11/07 Immune Glbulins Intravenus: Carimune NF, Flebgamma,
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationo Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17
Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals
(Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationMylotarg (gemtuzumab ozogamicin) (Intravenous)
Myltarg (gemtuzumab zgamicin) (Intravenus) Last Review Date: 09/19/2017 Date f Origin: 09/19/2017 Dates Reviewed: 09/2017 Dcument Number: IC-0320 I. Length f Authrizatin Newly-Diagnsed AML De nv disease
More informationIndications and Limitations of Coverage and/or Medical back to top
Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationCOVERAGE ELIGIBILITY OF SERVICES ASSOCIATED WITH A CANCER CLINICAL TRIAL
TRIAL Nn-Discriminatin Statement and Multi-Language Interpreter Services infrmatin are lcated at the end f this dcument. Cverage fr services, prcedures, medical devices and drugs are dependent upn benefit
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationNew Exception Status Benefits
FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Frmulary 1 x Next Review: 6/19 Pharmacy- Frmulary 2 x Date f Origin: 10/99 Grwth Stimulating Drugs: Nrditrpin Flexpr, Gentrpin,
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationKadcyla (ado-trastuzumab emtansine) Document Number: IC-0092
Kadcyla (ad-trastuzumab emtansine) Dcument Number: IC-0092 Last Review Date: 2/6/2018 Date f Origin: 05/16/2013 Dates Reviewed: 7/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 5/2015, 8/2015,
More informationPhysical, Occupational, and Speech Therapy - Children (Acute and Chronic)
Physical, Occupatinal, and Speech Therapy - Children (Acute and Chrnic) Infrmatin psted May 6, 2016 Nte: This article applies t claims submitted t TMHP fr prcessing. Fr claims prcessed by a Medicaid managed
More informationNutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:
Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin
More informationAdministrstrative Procedure
ELECTRONIC WORKING COPY VERIF. DATE: INITIALS: DIVISION: Envirnment, Safety, Health and Quality FUNCTIONAL AREA: Occupatinal Safety and Health SME: Garrick Schmburg Page 1 f 13 APPROVED BY/DATE: Steve
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationPerjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria
Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 295.4 T2 Effective Date: April 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1 BENEFIT
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hereditary Angioedema Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hereditary Angioedema (Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest,
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationDrug Therapy Guidelines
Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationHIP REPLACEMENT SURGERY (ARTHROPLASTY)
Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationOriginal Policy Date
MP 5.01.27 Thyrgen (Thyrtrpin Alfa) Medical Plicy Sectin Prescriptin Drug Issue 12:2013 Original Plicy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return t Medical Plicy
More informationS.K.J Construction Ltd Groundwork & Civil Engineering
S.K.J Cnstructin Ltd Grundwrk & Civil Engineering SUBSTANCE MISUSE POLICY 1 2 SUBSTANCE MISUSE POLICY 1 INTRODUCTION Plicy Aims Frm the viewpint f health and safety at wrk, SKJ Cnstructin Ltd (the Cmpany)
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationNumber: III-10 Effective Date: Feb 1999
Apprved By: Prvincial Systemic Prgram Cmmittee Revisin Date: Nv 1, 2016; Nv 30, 2017 Page 1 f 11 DIRECTIVE: In rder t ensure the safe prescribing, preparatin, dispensing and administratin f all systemic
More informationClinical Policy: Deutetrabenazine (Austedo) Reference Number: ERX.SPA.150 Effective Date:
Clinical Plicy: (Austed) Reference Number: ERX.SPA.150 Effective Date: 09.01.17 Last Review Date: 05.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal infrmatin.
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationAssessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA
Assessment criteria fr Primary Health Disciplines Eligibility fr Recgnitin as Credentialled Diabetes Educatr December 2015 ADEA ASSESSMENT CRITERIA FOR PRIMARY HEALTH DICIPLINES ELIGIBILITY FOR RECOGNITION
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationCoding. Training Guide
Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.
More informationcerliponase alfa (Brineura )
cerlipnase alfa (Brineura ) Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationAppendix C SCHEDULE OF BENEFITS FOR THE LOW COST MEDICAL PLAN OF BENEFITS
Appendix C SCHEDULE OF BENEFITS FOR THE LOW COST MEDICAL PLAN OF BENEFITS The schedule n the fllwing pages highlights key features f the Lw Cst Medical Plan f Benefits fr Cvered Individuals. These benefits
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationLow Molecular Weight Heparin Prescribing and Administration (Adults)
Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight
More information1100 Marie Mount Hall College Park, Maryland Tel: (301) Fax: (301)
UNIVERSITY SENATE 1100 Marie Munt Hall Cllege Park, Maryland 20742-7541 Tel: (301) 405-5805 Fax: (301) 405-5749 http://www.senate.umd.edu March 31, 2017 Jrdan Gdman Chair, University Senate 2208G Physical
More informationQP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #:
QP Energy Services LLC Hearing Cnservatin Prgram HSE Manual Sectin 7 Effective Date: 5/30/15 Revisin #: Prepared by: James Aregd Date: 5/30/15 Apprved by: James Aregd Date: 5/30/15 Page 1 f 8 Cntents Sectin
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More information5.0: Rare Bleeding Disorders
5.0: Rare Bleeding Disrders 5.1: General Infrmatin Rare bleeding disrders (RBDs) include deficiencies f factrs I (Fibringen), II, V, VII, X, XI and XIII. These deficiencies can be severe r mild. Severe
More informationCognitive enhancers for the treatment of Alzheimer s disease
Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class
More information2018 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26
More informationPROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.
Cmprehensive Diagnstic Evaluatin (CDE) Guidelines t Access the Applied Behavir Analysis (ABA) Benefit May 5, 2017 Clinical infrmatin that utlines medical necessity is required t supprt the need fr initial
More informationDESCRIPTION: Zemdri (plazomicin) is an aminoglycoside, which acts by binding to bacterial 30S ribosomal subunit, inhibiting protein synthesis.
What s New Medical Pharmaceutical Plicy March 2019 Updates MBP 187.0 Zemdri (plazmicin)- New plicy DESCRIPTION: Zemdri (plazmicin) is an aminglycside, which acts by binding t bacterial 30S ribsmal subunit,
More informationSchool Medication Authorization Form. School Grade Teacher. Emergency Phone No: To be completed by the student's physician: Name of Medication:
Schl Medicatin Authrizatin Frm Student's Name Address Birth Date Hme Phne Schl Grade Teacher Emergency Phne N: T be cmpleted by the student's physician: Name f Medicatin: Dsage Frequency Time t be given
More informationTransmittal 86 Date: July 3, SUBJECT: Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)
CMS Manual System Pub 100-03 Medicare Natinal Cverage Determinatins Department f Health & Human Services (DHHS) Centers fr Medicare & Medicaid Services (CMS) Transmittal 86 Date: July 3, 2008 Change Request
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationOriginal Policy Date
MP 7.01.113 Orthgnathic Surgery Medical Plicy Sectin Surgery Issue 12/2013 Original Plicy Date 12/2013 Last Review Status/Date Lcal Plicy created 12/2013 Return t Medical Plicy Index Disclaimer Our medical
More informationArtemis Physical Therapy Patient Information
Artemis Physical Therapy Patient Infrmatin Client Infrmatin Last Name First Name MI Address City Zip Date f Birth Female Male Emplyer (ptinal) Cntact Infrmatin Hme Phne Cell Phne Wrk Phne (ptinal) Email
More information